Kodu・Aktsiate loetelu・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Suletud

SektorTervishoid

26.4 0.34

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.1

Max

26.54

Põhinäitajad
By Trading Economics
Sissetulek	93M -92M
Müük	78M 214M
Aktsiakasum	-0.9
Kasumimarginaal	-42.991
Töötajad	1,371
EBITDA	94M -61M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+92.26% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	3. nov 2026

Turustatistika
By TradingEconomics
Turukapital	178M 2.6B
Eelmine avamishind	26.06
Eelmine sulgemishind	26.4

Uudiste sentiment

By Acuity

26%

74%

61 / 340 Pingereas Healthcare

Ultragenyx Pharmaceutical Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. aug 2026, 00:06 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, reaching a high of 2.96% following Friday's close amid broader economic concerns.

14. aug 2026, 22:51 UTC

Ultragenyx Pharmaceutical Inc shares rose in after-market trading, advancing significantly since Friday's close amid easing expectations for Federal Reserve interest rate hikes.

13. aug 2026, 19:16 UTC

Correlated Moves

Ultragenyx Pharmaceutical Inc. is declining, reflecting broader biotech sector weakness and a noted correlation with LABU's significant downturn.

12. aug 2026, 22:16 UTC

Ultragenyx Pharmaceutical shares are higher in after-market trading, reflecting positive price movement amid a stable monetary policy outlook and recent inflation data.

11. aug 2026, 19:36 UTC

News

Ultragenyx Pharmaceutical reached a settlement with Esjay Pharma over DOJOLVI patent litigation, allowing a generic version to launch in 2023. Shares are higher today.

10. aug 2026, 19:16 UTC

News

HC Wainwright reiterated its Buy rating on Ultragenyx Pharmaceutical, maintaining a $50 price target, contributing to shares trading higher during the session.

7. aug 2026, 20:03 UTC

News

Ultragenyx Pharmaceutical reported a loss of -$0.90 per share, beating estimates. Revenue of $214 million also exceeded expectations, but shares are trading roughly flat.

6. aug 2026, 23:21 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, showing unusual strength despite remaining below their 20-day moving average.

5. aug 2026, 19:52 UTC

News

Ultragenyx shares are lower after Wells Fargo cut its price target to $45. The company reported an EPS loss of $0.90, exceeding expectations.

4. aug 2026, 23:02 UTC

News

Ultragenyx Pharmaceutical reported second-quarter revenue of $214 million and narrowed its net loss to $92 million, with shares trading higher in after-market hours.

3. aug 2026, 22:51 UTC

Ultragenyx Pharmaceutical shares are trading roughly flat after-market. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

31. juuli 2026, 19:52 UTC

Correlated Moves

Ultragenyx Pharmaceutical is lower today amid a decline in the Biotechnology sub-sector, with shares near the lower end of their one-month range.

30. juuli 2026, 19:58 UTC

Correlated Moves

Ultragenyx rises, supported by SPDR S&P Biotech ETF gains.

29. juuli 2026, 18:43 UTC

Ultragenyx Pharmaceutical is lower today, continuing a decline amid broader market pressures from rising crude oil prices and geopolitical tensions.

28. juuli 2026, 19:03 UTC

Ultragenyx Pharmaceutical Inc shares are trading lower, reflecting a challenging performance backdrop amid strength in U.S. mega-cap stocks. No specific news was identified.

27. juuli 2026, 19:07 UTC

Ultragenyx Pharmaceutical Inc shares are higher as crude oil prices decline, easing geopolitical concerns. No specific company news was identified for the move.

24. juuli 2026, 19:51 UTC

Ultragenyx Pharmaceutical Inc shares are declining, continuing a trend of lower daily closes. Broader market volatility and new tariffs may be contributing factors.

22. juuli 2026, 19:36 UTC

Ultragenyx Pharmaceutical shares are declining amid rising crude oil prices due to U.S.-Iran tensions. The stock remains below its 20-day moving average.

21. juuli 2026, 19:22 UTC

Correlated Moves

Rising amid broader market gains and SPDR S&P Biotech support.

20. juuli 2026, 19:17 UTC

Correlated Moves

Ultragenyx Pharmaceutical is declining amid a broader downturn in the Biotechnology sector, continuing a trend of seven consecutive lower sessions.

Võrdlus sarnastega

Hinnamuutus

Ultragenyx Pharmaceutical Inc Prognoos

Hinnasiht

By TipRanks

92.26% tõus

12 kuu keskmine prognoos

Keskmine 50.93 USD 92.26%

Kõrge 96 USD

Madal 27 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Ultragenyx Pharmaceutical Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Ultragenyx Pharmaceutical Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

61 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.